Parkinson’s disease cell therapy-focused Aspen Neuroscience and bispecific biotech Bambusa Therapeutics are the latest drug ...

Becton, Dickinson and Company has named Ferass Abuzaina as its new Worldwide President of its Surgery business unit. | Becton ...

GSK has joined Chai Discovery’s growing roster of Big Pharma clients, signing up to access protein-folding and design models.

Welcome to this week's Chutes & Ladders, our roundup of significant leadership hirings, firings and retirings across the ...

What does it mean to be a Fierce 15 biotech in 2026? With this year’s list unveiled, the Fierce Biotech team gets together to ...

Endeavor BioMedicines has solidified its potential threat to Big Pharma with a phase 2b readout suggesting its Hedgehog inhibitor could become the first drug to reduce lung fibrosis while increasing ...

Iambic Therapeutics is aiming for a $135 million IPO in net proceeds as the AI biotech looks to fund the clinical development ...

To a passerby, the glass-fronted 10 Prospect building rising above the low-slung restaurant and retail space of Somerville's ...

Japan’s Ono Pharmaceutical is paying $80 million upfront for the regional rights to a trio of Biohaven’s IgG degraders led by ...

Zealand Pharma has reported more phase 2 data on its Roche-partnered amylin analog, linking the drug candidate to competitive ...

A phase 2 celiac disease trial of argenx’s FB102 has hit its primary endpoint, delivering a boost to a drug candidate that ...

Cadrenal Therapeutics, a heart-focused biotech that recently reached an agreement with the FDA on the design of a pivotal ...